COMMUNIQUÉS West-GlobeNewswire

Madrigal Pharmaceuticals Appoints Shannon Kelley as General Counsel
02/08/2024
CONSHOHOCKEN, Pa., Aug. 02, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis (NASH), today [...]
Algernon Pharmaceuticals Announces Closing of Private Placement
02/08/2024
VANCOUVER, British Columbia, Aug. 02, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) (the “ Company ” or “ Algernon ”) a Canadian clinical stage pharmaceutical [...]
Adverum Biotechnologies to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
02/08/2024
REDWOOD CITY, Calif., Aug. 02, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular [...]
The Ensign Group Grows in Colorado
02/08/2024
SAN JUAN CAPISTRANO, Calif., Aug. 02, 2024 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign TM group of companies, which invest in and provide skilled nursing and senior living [...]
BrightSpring Health Services, Inc. Reports Second Quarter 2024 Financial Results and Increases Full Year 2024 Guidance
02/08/2024
LOUISVILLE, Ky., Aug. 02, 2024 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. (“BrightSpring” or the “Company”) (NASDAQ: BTSG), a leading provider of home and community-based health services for complex [...]
The Ensign Group Acquires Skilled Nursing Facility in Iowa
02/08/2024
SAN JUAN CAPISTRANO, Calif., Aug. 02, 2024 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign TM group of companies, which invest in and provide skilled nursing and senior living [...]
The Ensign Group Acquires Skilled Nursing Facility in Colorado
02/08/2024
SAN JUAN CAPISTRANO, Calif., Aug. 02, 2024 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign TM group of companies, which invest in and provide skilled nursing and senior living [...]
EUROBIO SCIENTIFIC COMPLETES ACQUISITION OF ENDOPREDICT® GENOMIC TEST FROM MYRIAD GENETICS
02/08/2024
EUROBIO SCIENTIFIC COMPLETES ACQUISITION OF ENDOPREDICT ® GENOMIC TEST FROM MYRIAD GENETICS Paris, August 2 nd , 2024 –7:30 am Eurobio Scientific (FR0013240934, ALERS), a leading French group in in vitro specialty [...]
EUROBIO SCIENTIFIC FINALISE L’ACQUISITION DU TEST GÉNOMIQUE ENDOPREDICT® AUPRÈS DE MYRIAD GENETICS
02/08/2024
EUROBIO SCIENTIFIC FINALISE L’ACQUISITION DU TEST GÉNOMIQUE ENDOPREDICT ® AUPRÈS DE MYRIAD GENETICS Paris, le 2 août 2024 –7h30 Eurobio Scientific (FR0013240934, ALERS, éligible PEA-PME), groupe français leader dans le [...]
PolyPid Announces Private Placement for Up to $14 Million in Gross Proceeds
02/08/2024
Funding Extends Company’s Cash Runway into Second Quarter 2025, which is beyond the Anticipated Timing for SHIELD II Top-line Results if Warrants are Fully Exercised More than 300 Patients Enrolled in Ongoing SHIELD II [...]
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/08/2024
RESEARCH TRIANGLE PARK, N.C., Aug. 01, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX ), a commercial-stage oncology company, today announced the grant of inducement stock options exercisable for 12,300 [...]
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/08/2024
SAN DIEGO, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics [...]
Supernus Resubmits NDA for SPN-830 Apomorphine Infusion Device
01/08/2024
ROCKVILLE, Md., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system [...]
FDA Grants Orphan Drug Designation to Cellectis’ CLLS52 (alemtuzumab) For ALL Treatment
01/08/2024
NEW YORK, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving [...]
La FDA accorde le statut de médicament orphelin à CLLS52 (alemtuzumab) de Cellectis pour le traitement de la LLA
01/08/2024
NEW YORK, 01 août 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS) (la « Société »), société de biotechnologie de stade clinique, qui utilise sa technologie pionnière d'édition de génome TALEN [...]
Interpace Biosciences Announces Record Second Quarter 2024 Financial and Business Results
01/08/2024
● Q2 Revenue of $12.0 million; a $1.0M and 9% increase year-over-year ● Q2 Test volume up 12% year-over-year to record levels ● Q2 Cash collections of $11.0M; a $0.7M and 7% increase year-over-year ● Q2 Volume, Revenue [...]
The Pennant Group Announces New $250 Million Credit Facility
01/08/2024
EAGLE, Idaho, Aug. 01, 2024 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of the Pennant group of affiliated home health, hospice and senior living companies, today announced that the [...]
CENTOGENE Publication in Brain Journal Reveals 15% of Parkinson’s Disease Cases Are Linked to Genetic Factors
01/08/2024
Initial data from largest international Parkinson’s disease patient cohort shows approximately 90% of these genetically confirmed patients had variants in the LRRK2 or GBA1 genes, making these individuals potential [...]
ARCA biopharma Announces Second Quarter 2024 Financial Results and Provides Corporate Update
01/08/2024
WESTMINSTER, Colo., Aug. 01, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), (the “Company”) a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies [...]

Pages